Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Elite Investors Disagree With Saudi Prince On Twitter, Like This Trending Biotech

Page 1 of 2

Shares of Twitter Inc (NYSE:TWTR) and Biogen Inc (NASDAQ:BIIB) are up by 4% and 2.4% respectively in afternoon trading, as investors become more optimistic about the two companies’ prospects. An SEC filing showed that Prince Alwaleed bin Talal and his holding company recently raised their stake to 5,17% of the social media giant, owning just under 34.95 million shares. Meanwhile, Biogen is slated to present positive data on TECFIDERA, the company’s drug for the treatment of relapsing forms of multiple sclerosis. Let’s take a closer look at the two companies and examine how the smart money thinks of them.

Twitter Inc (NYSE:TWTR), Logo, Sign, Phone, Display, Smarphone, Page

Quka /

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 118%, over two-times greater returns than the S&P 500 during the same period (see more details).

Prince Alwaleed bin Talal’s purchase is a vote of confidence for Twitter Inc (NYSE:TWTR), as shares of the social media company have fallen by 23% year-to-date amid investor worries over flagging user growth and failed monetization efforts. Talal is as astute as they come and his purchase makes the Saudi Prince the second-largest holder of Twitter shares.

Founder and new CEO Jack Dorsey will have to decide whether to change Twitter’s strict 140 character limit and whether additional acquisitions or an outright sale to Google might be better for Twitter shareholders. Twitter has failed to realize the Instagram-like traction from its acquisitions that Facebook Inc (NASDAQ:FB) has, but has refused to sell itself. Dorsey is widely regarded as a visionary in his own right and many investors are confident in his ability to steer Twitter. Talal’s purchase is just the latest such example of savvy investors betting on him.

Follow Twitter Inc. (NYSE:TWTR)
Trade (NYSE:TWTR) Now!

Although Talal added to his bullish position on Twitter, our data shows that hedge funds were for the most part bearish on the company in the second quarter. The total number of hedge funds long Twitter Inc (NYSE:TWTR) declined to 47 from 64 in the quarter, while the total value of hedge funds’ holdings declined to $701 million or 2.9% of the float, from $1.75 billion held at the end of March. David Shaw‘s D. E. Shaw increased its position of put options on Twitter by 115% to 2.2 million underlying shares, while Daniel Benton’s Andor Capital Management cut its long position by 63% to 1.5 million shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!